ResistAid Enhances Immunity

ALLENDALE, N.J.According to a recent  randomized, double blind, placebo-controlled, parallel-group pilot study, the proprietary arabinogalactan extract (as ResistAid, from Lonza) increased the antibody response of healthy volunteers to the 23-valent pneumococcal vaccine compared to placebo (Nutri J. 2010;9:32). The study was conducted in collaboration with Medicus Research LLC in Northridge, Calif. and published in the August issue of Nutrition Journal. Its findings confirm the ability of ResistAid to provide a selective response from the immune system.

 The results of this group study demonstrate the ability of ResistAid to selectively enhance the antibody response to the pneumococcal vaccine," said Jay Udani, M.D., CPI, the principal investigator of the study and CEO of Medicus Research.  "Modulating the immune system in direct response to antigenic stimulation rather than nonspecific augmentation represents a more physiologic approach to immune enhancement."

The study showed vaccinated volunteers who received ResistAid for 30 days prior to the vaccine and up till day 72 demonstrated significantly higher pneumococcal IgG levels in two antibodies subtypes (18C and 23F) at both day 51 and at day 72 than the group that received placebo. These same subtypes (18C and 23F) also demonstrated statistically significant change scores from baseline in the ResistAid group at day 51 and at day 72.